371 related articles for article (PubMed ID: 18656459)
1. Low doses of cyclic AMP-phosphodiesterase inhibitors rapidly evoke opioid receptor-mediated thermal hyperalgesia in naïve mice which is converted to prominent analgesia by cotreatment with ultra-low-dose naltrexone.
Crain SM; Shen KF
Brain Res; 2008 Sep; 1231():16-24. PubMed ID: 18656459
[TBL] [Abstract][Full Text] [Related]
2. Naloxone rapidly evokes endogenous kappa opioid receptor-mediated hyperalgesia in naïve mice pretreated briefly with GM1 ganglioside or in chronic morphine-dependent mice.
Crain SM; Shen KF
Brain Res; 2007 Sep; 1167():31-41. PubMed ID: 17692296
[TBL] [Abstract][Full Text] [Related]
3. Acute thermal hyperalgesia elicited by low-dose morphine in normal mice is blocked by ultra-low-dose naltrexone, unmasking potent opioid analgesia.
Crain SM; Shen KF
Brain Res; 2001 Jan; 888(1):75-82. PubMed ID: 11146054
[TBL] [Abstract][Full Text] [Related]
4. Cholera toxin-B subunit blocks excitatory opioid receptor-mediated hyperalgesic effects in mice, thereby unmasking potent opioid analgesia and attenuating opioid tolerance/dependence.
Shen KF; Crain SM
Brain Res; 2001 Nov; 919(1):20-30. PubMed ID: 11689159
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of cAMP accumulation by kappa-receptor activation in isolated iris-ciliary bodies: role of phosphodiesterase and protein kinase C.
Dortch-Carnes J; Potter DE
J Pharmacol Exp Ther; 2002 May; 301(2):599-604. PubMed ID: 11961062
[TBL] [Abstract][Full Text] [Related]
6. Acute and chronic fentanyl administration causes hyperalgesia independently of opioid receptor activity in mice.
Waxman AR; Arout C; Caldwell M; Dahan A; Kest B
Neurosci Lett; 2009 Oct; 462(1):68-72. PubMed ID: 19559072
[TBL] [Abstract][Full Text] [Related]
7. Oxycodone plus ultra-low-dose naltrexone attenuates neuropathic pain and associated mu-opioid receptor-Gs coupling.
Largent-Milnes TM; Guo W; Wang HY; Burns LH; Vanderah TW
J Pain; 2008 Aug; 9(8):700-13. PubMed ID: 18468954
[TBL] [Abstract][Full Text] [Related]
8. Morphine hyperalgesia in mice is unrelated to opioid activity, analgesia, or tolerance: evidence for multiple diverse hyperalgesic systems.
Juni A; Klein G; Kest B
Brain Res; 2006 Jan; 1070(1):35-44. PubMed ID: 16409995
[TBL] [Abstract][Full Text] [Related]
9. Ultra-low doses of naltrexone or etorphine increase morphine's antinociceptive potency and attenuate tolerance/dependence in mice.
Shen KF; Crain SM
Brain Res; 1997 May; 757(2):176-90. PubMed ID: 9200746
[TBL] [Abstract][Full Text] [Related]
10. Ultra-low concentrations of naloxone selectively antagonize excitatory effects of morphine on sensory neurons, thereby increasing its antinociceptive potency and attenuating tolerance/dependence during chronic cotreatment.
Crain SM; Shen KF
Proc Natl Acad Sci U S A; 1995 Nov; 92(23):10540-4. PubMed ID: 7479836
[TBL] [Abstract][Full Text] [Related]
11. Mu antagonist and kappa agonist properties of beta-funaltrexamine (beta-FNA) in vivo: long-lasting spinal analgesia in mice.
Qi JA; Heyman JS; Sheldon RJ; Koslo RJ; Porreca F
J Pharmacol Exp Ther; 1990 Mar; 252(3):1006-11. PubMed ID: 2156986
[TBL] [Abstract][Full Text] [Related]
12. Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in mu opioid receptor-G protein coupling and Gbetagamma signaling.
Wang HY; Friedman E; Olmstead MC; Burns LH
Neuroscience; 2005; 135(1):247-61. PubMed ID: 16084657
[TBL] [Abstract][Full Text] [Related]
13. Peripheral mu-, kappa- and delta-opioid receptors mediate the hypoalgesic effect of celecoxib in a rat model of thermal hyperalgesia.
Correa JD; Paiva-Lima P; Rezende RM; Dos Reis WG; Ferreira-Alves DL; Bakhle YS; Francischi JN
Life Sci; 2010 Jun; 86(25-26):951-6. PubMed ID: 20451533
[TBL] [Abstract][Full Text] [Related]
14. Ultra-low dose naloxone restores the antinociceptive effect of morphine in pertussis toxin-treated rats by reversing the coupling of mu-opioid receptors from Gs-protein to coupling to Gi-protein.
Tsai RY; Tai YH; Tzeng JI; Cherng CH; Yeh CC; Wong CS
Neuroscience; 2009 Dec; 164(2):435-43. PubMed ID: 19682558
[TBL] [Abstract][Full Text] [Related]
15. Naltrexone in vivo protects mu receptors from inactivation by beta-funaltrexamine, but not kappa receptors from inactivation by nor-binaltorphimine.
Paronis CA; Waddell AB; Holtzman SG
Pharmacol Biochem Behav; 1993 Dec; 46(4):813-7. PubMed ID: 8309960
[TBL] [Abstract][Full Text] [Related]
16. Interaction between the antidepressant-like behavioral effects of beta adrenergic agonists and the cyclic AMP PDE inhibitor rolipram in rats.
Zhang HT; Huang Y; Mishler K; Roerig SC; O'Donnell JM
Psychopharmacology (Berl); 2005 Oct; 182(1):104-15. PubMed ID: 16010541
[TBL] [Abstract][Full Text] [Related]
17. Carboxyamidotriazole: a novel inhibitor of both cAMP-phosphodiesterases and cGMP-phosphodiesterases.
Guo L; Luo L; Ju R; Chen C; Zhu L; Li J; Yu X; Ye C; Zhang D
Eur J Pharmacol; 2015 Jan; 746():14-21. PubMed ID: 25446933
[TBL] [Abstract][Full Text] [Related]
18. Morphine-6beta-glucuronide rapidly increases pain sensitivity independently of opioid receptor activity in mice and humans.
van Dorp EL; Kest B; Kowalczyk WJ; Morariu AM; Waxman AR; Arout CA; Dahan A; Sarton EY
Anesthesiology; 2009 Jun; 110(6):1356-63. PubMed ID: 19461298
[TBL] [Abstract][Full Text] [Related]
19. Effects of rolipram on in vivo dopamine receptor binding.
Hosoi R; Ishikawa M; Kobayashi K; Gee A; Yamaguchi M; Inoue O
J Neural Transm (Vienna); 2002 Sep; 109(9):1139-49. PubMed ID: 12203041
[TBL] [Abstract][Full Text] [Related]
20. delta-Opioid receptor activates cAMP phosphodiesterase activities in neuroblastoma x glioma NG108-15 hybrid cells.
Law PY; Loh HH
Mol Pharmacol; 1993 May; 43(5):684-93. PubMed ID: 8388986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
